Citation only
via Europe PMC
Postbiotics as a therapeutic frontier in Parkinson's disease: Insights into molecular pathways and neuroprotective effects.
Metabolic brain disease · 2026
Dysbiosis
Mitochondrial dysfunction
Altered intercellular communication
Chronic inflammation
Human
Preclinical / animal
Review
Abstract
Parkinson's disease (PD) is an aging neurodegenerative disease associated with dopaminergic neuronal impairment, mitochondrial dysfunction(definition), oxidative stress, chronic neuroinflammation, and pathological deposits of misfolded α-synuclein. Gut microbiota (GM) is a general contributing factor in PD pathogenesis via the microbiota-gut-brain bidirectional axis. Gut dysbiosis facilitates intestinal permeability, systemic inflammation, disrupted metabolism of neurotransmitters and amplified α-synuclein aggregation, deteriorates motor and non-motor symptoms. These bioactive metabolites and structural components that beneficial microorganisms generate, known as postbiotics, have been highlighted as having the capacity to regulate neuroinflammation, mitochondrial functionality, synaptic signaling, gut and blood-brain barrier integrity. Short-chain fatty acids (SCFAs), bioactive peptides, bacterial lysates, and exopolysaccharides are compounds with potent neuroprotective and anti-inflammatory properties that are applicable to PD. Preclinical evidence shows that postbiotics, especially butyrate, have the ability to alleviate oxidative stress, inhibit microglial activation, prevent α-synuclein aggregation, and improve behavioral performance in PD models. The emerging clinical evidence also indicates that the optimization of endogenous postbiotic synthesis positively influences gastrointestinal (GI) symptoms and decreases inflammatory biomarkers, and changes GM in PD patients. This review summarizes the mechanistic activities of postbiotics on pathways involved in the pathogenesis of PD and synthesizes recent findings of the therapeutic usefulness of postbiotics. Overall, postbiotics may represent a promising therapeutic strategy for targeting neurodegenerative processes in PD, although their safety, efficacy, optimal dosing, and clinical utility require further investigations. Further studies of specific postbiotic interventions and strategies targeting the microbiota-gut-brain axis are needed to determine their potential to improve the quality of life of patients with PD.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.1007/s11011-026-01978-7
- Canonical
- link ↗
- Fetched
- 2026-10-10 MST
Cite this
APA
A, K., & KR., A. (2026). Postbiotics as a therapeutic frontier in Parkinson's disease: Insights into molecular pathways and neuroprotective effects. <em>Metabolic brain disease</em>. https://doi.org/10.1007/s11011-026-01978-7
Vancouver
A K, KR. A. Postbiotics as a therapeutic frontier in Parkinson's disease: Insights into molecular pathways and neuroprotective effects. Metabolic brain disease. 2026. doi:10.1007/s11011-026-01978-7.
BibTeX
@article{kumari2026Postbi,
title = {Postbiotics as a therapeutic frontier in Parkinson's disease: Insights into molecular pathways and neuroprotective effects.},
author = {Kumari A and Aran KR.},
journal = {Metabolic brain disease},
year = {2026},
doi = {10.1007/s11011-026-01978-7},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Nutrients 2026
Citation only
Gut Microbiome-Mediated Neuroprotective Effect of the Mediterranean Diet: A Narrative Review of Cognitive Aging, Alzheimer's Disease, and Parkinson's Disease.
Molecular neurobiology 2026
Citation only
A Comprehensive Review on the Microbial Signatures and Metabolic Mechanisms Underlying the Gut-Alzheimer's Disease Axis.
Brain 2021
Open access · OA
The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options
Frontiers in Nutrition 2026
Open access · CC-BY
Targeting cellular senescence through nutritional senotherapeutics in brain aging and neurodegenerative diseases
Frontiers in nutrition 2026
Open access · OA
Targeting cellular senescence through nutritional senotherapeutics in brain aging and neurodegenerative diseases.
Current nutrition reports 2026
Citation only